Investigating the Impact of Delivery System Design on the Efficacy of Self-Amplifying RNA Vaccines

被引:38
|
作者
Anderluzzi, Giulia [1 ,2 ]
Lou, Gustavo [1 ,2 ]
Gallorini, Simona [2 ]
Brazzoli, Michela [2 ]
Johnson, Russell [3 ]
O'Hagan, Derek T. [3 ]
Baudner, Barbara C. [2 ]
Perrie, Yvonne [1 ]
机构
[1] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow G4 0RE, Lanark, Scotland
[2] GSK, I-53100 Siena 1, Italy
[3] GSK, Rockville, MD USA
基金
欧盟地平线“2020”;
关键词
self-amplifying RNA; liposomes; polymeric nanoparticles; solid lipid nanoparticles; emulsions; antigen expression; immunogenicity; SOLID-LIPID NANOPARTICLES; GENE-THERAPY; ADJUVANT FORMULATIONS; PROTECTIVE EFFICACY; NONVIRAL DELIVERY; IMMUNE-RESPONSES; DNA VACCINATION; SIRNA DELIVERY; PLASMID DNA; LIPOSOMES;
D O I
10.3390/vaccines8020212
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
messenger RNA (mRNA)-based vaccines combine the positive attributes of both live-attenuated and subunit vaccines. In order for these to be applied for clinical use, they require to be formulated with delivery systems. However, there are limited in vivo studies which compare different delivery platforms. Therefore, we have compared four different cationic platforms: (1) liposomes, (2) solid lipid nanoparticles (SLNs), (3) polymeric nanoparticles (NPs) and (4) emulsions, to deliver a self-amplifying mRNA (SAM) vaccine. All formulations contained either the non-ionizable cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) or dimethyldioctadecylammonium bromide (DDA) and they were characterized in terms of physico-chemical attributes,in vitro transfection efficiency and in vivo vaccine potency. Our results showed that SAM encapsulating DOTAP polymeric nanoparticles, DOTAP liposomes and DDA liposomes induced the highest antigen expression in vitro and, from these, DOTAP polymeric nanoparticles were the most potent in triggering humoral and cellular immunity among candidates in vivo.
引用
收藏
页数:22
相关论文
共 50 条
  • [21] Self-Amplifying Replicon RNA Delivery to Dendritic Cells by Cationic Lipids
    Englezou, Pavlos C.
    Sapet, Cedric
    Demoulins, Thomas
    Milona, Panagiota
    Ebensen, Thomas
    Schulze, Kai
    Guzman, Carlos-Alberto
    Poulhes, Florent
    Zelphati, Olivier
    Ruggli, Nicolas
    McCullough, Kenneth C.
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2018, 12 : 118 - 134
  • [22] Self-amplifying vectors for gene delivery
    Herweijer, H
    Wolff, JA
    ADVANCED DRUG DELIVERY REVIEWS, 1997, 27 (01) : 5 - 16
  • [23] VACCINES Self-amplifying RNA in lipid nanoparticles: a next-generation vaccine?
    Flemming, Alexandra
    NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (10) : 749 - 749
  • [24] Production, Characterization, and Assessment of Permanently Cationic and Ionizable Lipid Nanoparticles for Use in the Delivery of Self-Amplifying RNA Vaccines
    Kairuz, Dylan
    Samudh, Nazia
    Ely, Abdullah
    Arbuthnot, Patrick
    Bloom, Kristie
    PHARMACEUTICS, 2023, 15 (04)
  • [25] Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19
    Silva-Pilipich, Noelia
    Beloki, Uxue
    Salaberry, Laura
    Smerdou, Cristian
    VACCINES, 2024, 12 (03)
  • [26] Self-Amplifying Replicon RNA Vaccine Delivery to Dendritic Cells by Synthetic Nanoparticles
    McCullough, Kenneth C.
    Milona, Panagiota
    Thomann-Harwood, Lisa
    Demoulins, Thomas
    Englezou, Pavlos
    Suter, Rolf
    Ruggli, Nicolas
    VACCINES, 2014, 2 (04): : 735 - 754
  • [27] Self-amplifying RNA virus vectors: clinical applications in cancer drug delivery
    Lundstrom, Kenneth
    EXPERT OPINION ON DRUG DELIVERY, 2019, 16 (10) : 1027 - 1029
  • [28] Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens
    Maruggi, Giulietta
    Chiarot, Emiliano
    Giovani, Cinzia
    Buccato, Scilla
    Bonacci, Stefano
    Frigimelica, Elisabetta
    Margarit, Immaculada
    Geall, Andrew
    Bensi, Giuliano
    Maione, Domenico
    VACCINE, 2017, 35 (02) : 361 - 368
  • [29] Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses
    Vogel, Annette B.
    Lambert, Laura
    Kinnear, Ekaterina
    Busse, David
    Erbar, Stephanie
    Reuter, Kerstin C.
    Wicke, Lena
    Perkovic, Mario
    Beissert, Tim
    Haas, Heinrich
    Reece, Stephen T.
    Sahin, Ugur
    Tregoning, John S.
    MOLECULAR THERAPY, 2018, 26 (02) : 446 - 455
  • [30] Self-amplifying RNA vaccines against antigenically distinct SARS-CoV-2 variants
    Herfst, Sander
    de Vries, Rory D.
    LANCET INFECTIOUS DISEASES, 2024, 24 (04): : 330 - 331